1 January 2002 in World Journal of Gastroenterology
To detect the expression of soluble TRAIL (TNF-related apoptosis inducing ligand, TRAIL) in the peripheral blood of HBV infected patients and try to elucidate whether the expression level of sTRAIL have any correlativity with the clinical staging, the expression level of HBV markers and the degree of liver damage. 52 cases of HBV infected patients were investigated, including 8 HBV carriers, 30 chronic hepatitis B, 11 cirrhotics and 3 HBV infection related hepatocellular carcinoma. Expression of soluble TRAIL and markers of the hepatitis B were measured by enzyme-linked immunosorbent assay. The expression level of sTRAIL in the peripheral blood of the HBV infected patients was significantly higher than that of healthy controls (1378.35+/-540.23 pg/ml vs 613.75+/-175.80 pg/ml, P<0.001). In the group of chronic hepatitis, the expression level of sTRAIL was coincident with the status of the disease and was significantly correlated with the level of ALT. In the group of cirrhosis and liver cancer, its expression level was significantly higher than that of the healthy persons and HBV carriers, but lower than that of the hepatitis B patients; meanwhile, the expression of sTRAIL did not have any correlativity with the functional indexes of the liver. The soluble TRAIL in the HBV infected people may participate in the liver damage. Our results indicated that the expression level of soluble TRAIL may reflect the ravage of liver caused by host immune reaction to a certain degree.
14 August 2007 in Apoptosis
1 May 2005 in Science China Life Sciences
1 April 2009 in The Journal of Immunology
Hepatitis B virus (HBV) infection afflicts more than 300 million people worldwide .TRAIL, the TNF-related apoptosis-inducing ligand, has recently been implicated in hepatocyte death during HBV infection. The goal of our study is to determine for the first time whether HBV core protein (HBc) is involved in modulating the TRAIL apoptotic pathway. Using cck-8 and TUNEL assay we firstly reported the HBV core protein (HBc) is a potent inhibitor of TRAIL-induced apoptosis. The further study showed that HBc decreased the expression of DR5, which is one of the most important TRAIL receptors. Additionally , the dual-luciferase assay indicated HBc significantly repressed the promoter activity of the human DR5 gene.Our further results examed by the microarray analysis indicated that HBc also repressed P53 gene. Whether the HBc-p53 pathway plays a significant role in regulating DR5 expression needs to be further studied. These results indicate that HBc may prevent hepatocytes from TRAIL-induced apoptosis by blocking DR5 expression, which in turn contributes to the development of chronic hepatitis and HCC. This work was supported by grants from the National Natural Science Foundation of China ( No.30700973, No.30772031, No.30128023 and No.30700357). Corresponding author E-mail : WSW@sdu.edu.cn. Wensheng Sun , Juan Du and Xiaohong Liang contributed equally to this work.
1 April 2009 in The Journal of Immunology
Metastatic hepatoma cells are the most dangerous parts in hepatocarcinoma patients.We want to study the mechanism of metastatic hepatoma cells to escaping from host immune attacks. Firstly, we constructed the metastatic hepatoma cell model by using plates pre-coated with Poly-HEMA and found that they were aggregated, proliferation-resistant, apoptosis-resistant, cell cycle arrested and more invasive. These metastatic hepatoma cells could settled down and proliferated again under suitable conditions. Subsequently,we investigated the response of metastatic hepatoma cells to the typical immune surveillant molecule TNF-related apoptosis-inducing ligand (TRAIL). The data indicated that metastatic hepatoma cells not only resist to TRAIL-induced apoptosis, but also express lower membrane binding TRAIL and excrete more soluble TRAIL (sTRAIL) to exert a stealth "tumor counterattack" effect to attack immune effector cells. Deeply study found that the membrane binding death receptors DR4 and DR5 were down-regulated on metastatic BEL7402 and SMMC7721 cells and that their active level of caspase-8,-9,-3 was highly restrained. So we concluded that metastatic hepatoma cells could escape from host immune system by the death receptor pathway. This work was supported by grants from the National Natural Science Foundation of China (No.30873025, No.30700357 and No.30772031), Corresponding author E-mail:WSW@sdu.edu.cn.
1 April 2009 in The Journal of Immunology
Hepatitis B virus (HBV) transgenic mice invariably developed macroscopically evident tumors within the 20th month of life. Thus HBV transgenic mouse can be used as a natural model of hepatocellular carcinoma (HCC). We confirmed this phenomenon by observation of BALB/c mice harboring HBV complete genome (subtype ayw). To identify molecular changes involved in HCC, we performed both microarray profiling and proteomic analysis between HBV transgenic mice and their syngeneic controls at 6, 12, and 20-month-old. The total liver RNA was hybridized on an oligonucleotide chip containing 35,000 Mus musculus genes. The total liver protein was used for proteomic analysis. Out of all genes and proteins compared and screened, the number of differentially expressed transcripts and proteins was increased along with the growth of mice. We concluded a molecular portrait in different stages of HCC. These molecules were involved in important cellular pathways, including cell growth regulation, apoptosis, immune response, metabolisms, stress, cell adhesion, et al. The dynamics of molecular profiling during hepatocellular carcinogenesis would better elucidate the molecular mechanisms of HCC and help for the discovery of novel therapeutic targets. Correspondence to Wensheng Sun: wsw@sdu.edu.cn Supported by the National Nature Science Foundation of China, Grant No. 30440040, 30772031, and 30801036.